Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes

JAMA

Volumn 295, Issue 14, 2006, Pages 1681-1687

  Monnier, Louis ^a,b   Mas, Emilie ^a   Ginet, Christine ^a   Michel, Françoise ^a   Villon, Laetitia ^a   Cristol, Jean Paul ^a   Colette, Claude ^a  

^a UNIV MONTPELLIER   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CREATININE; GLUCOSE; HEMOGLOBIN A1C; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CALCULATION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DRUG EXCRETION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINARY EXCRETION; CHRONIC DISEASE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; URINE;

AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DINOPROST; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; LINEAR MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 33645745733     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.14.1681     Document Type: Article

References (56)

1. Kannel WB, Mc Gee DL. Diabetes and cardiovascular diseases: the Framingham Study. JAMA. 1979;241:2035-2038.
2. Laakso L, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5:294-315.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. Stratton IM, Alder AI, Neil HAW, et al; UK Prospective Diabetes Study Group. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321:405-412.
5. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM 1: model constructions and assumptions. Diabetes Care. 1997;20:725-734.
6. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
7. A1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
8. Klein R. Hyperglycemia and microvascular disease in diabetes. Diabetes Care. 1995;18:258-268.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
10. Brownlee M. The pathophysiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
11. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46(suppl 1):M9-M16.
12. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes. Diabetologia. 2001;44:2107-2114.
13. Ceriello A, Hanefeld M, Leiter L, et al; International Prandial Glucose Regulation (PGR) Study Group. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164:2090-2095.
14. A1c. Diabetes Care. 2003;26:881-885.
15. Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hyperglycemia and hyperinsulinemia? Diabetes Care. 2002;25:889-893.
16. Metzger M, Leibovitz G, Wainstein J, Glaser B, Raz Y. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care. 2002;25:1185-1191.
17. Klonoff DC. Continuous glucose monitoring roadmap for 21st century therapy. Diabetes Care. 2005;28:1231-1239.
18. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-9387.
19. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28:505-513.
20. Cockcroft DW, Gault HM. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
21. Directive 2001/20/CE of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. May 1, 2001: L121/34. Available at: http://europa.eu.int/eur-lex/pri/en/oj/dat/2001/l_121/ l_12120010501en00340044.pdf. Accessibility verified March 17, 2006.
22. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem. 1972;18:499-502.
23. Dole VP. Fractionation of plasma non esterified fatty acids. J Clin Invest. 1956;35:150-154.
24. Schwedhelm E, Böger RH. Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin Chem Lab Med. 2003;41:1552-1561.
25. Bessard J, Cracowski JL, Stanke-Labesque F, Bessard G. Determination of isoprostaglandin F2α type III in human urine by gas chromatography- electronic impact mass spectrometry: comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl. 2001;754:333-343.
26. Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal. 2005;7:256-268.
27. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644-655.
28. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care. 1987;10:225-237.
29. Zar JH. Biostatistical Analysis. 4th ed. Upper Saddle River, NJ: Prentice Hall Inc; 1999:663.
30. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S36.
31. Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care. 2003;26:582-589.
32. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective of an old paradigm. Diabetes. 1999;48:1-9.
33. Montero A, Munger KA, Khan RZ, et al. F2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 2000;58:1963-1972.
34. Basu S. Metabolism of 8-iso-prostaglandin F2α. FEBS Lett. 1998;428:32-36.
35. Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol. 2005;5:198-203.
36. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224-229.
37. Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107:3199-3203.
38. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002;25:537-541.
39. Stojiljkovic MP, Lopes HF, Zhang D, et al. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens. 2002;20:1215-1221.
40. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
41. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-epi prostaglandin F2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230-3235.
42. Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
43. Fava D, Cassone-Faldetta M, Laurenti O, et al. Gliclazide improves anti-oxidant status and nitric oxidemediated vasodilatation in type 2 diabetes. Diabet Med. 2002;19:752-757.
44. Desideri G, Croce G, Tucci M, et al. Effects of bezafibrate and simvastatin on endothelial and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003;88:5341-5347.
45. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal. 2005;7:221-235.
46. Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev. 1997;5:365-391.
47. Taskinen M-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.
48. Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Rev. 1997;5:316-330.
49. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P; Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
50. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54:1-7.
51. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486-494.
52. Ceriello A, Quagliano L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25:1439-1443.
53. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care. 2002;25:737-741.
54. Trovati M, Burzacca S, Mularovi E, et al. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycemic agents: importance of blood glucose monitoring. Diabetologia. 1991;34:662-667.
55. Monnier L, Colette C, Lapinski H. Global assessment for quality and safety of control in type 2 diabetic patients. Eur J Clin Invest. 2004;34:37-42.
56. Monnier LH, Lachkar H, Richard J-L, et al. Plasma β-thromboglobulin response to insulin-induced hypoglycemia in type 1 diabetic patients. Diabetes. 1984;33:907-909.